Mesothelioma Cancer Centers

The Vanderbilt-Ingram Cancer Center is at the forefront of lung cancer and mesothelioma treatment, providing screenings, second opinions and individualized treatment for a patient’s cancer.

Specialists at the Vanderbilt-Ingram Cancer Center have experience diagnosing the disease, as well as providing second opinions, with a variety of tests like CT scans, MRIs and endoscopic ultrasounds. The center provides a variety of treatment options depending on the patient’s individual case, including advanced robotic surgery, minimally invasive surgery, immunotherapy, radiation and chemotherapy. Radiation is used as a treatment or as a palliative therapy to reduce symptoms and manage pain. The center offers targeted therapy, biologic therapy and clinical trials to patients as alternative treatment options, as well. They assess the cancer on an individual basis, using genetic testing to find the best treatment options.

Patient navigators are also available to patients to relieve them of the stress of scheduling appointments and collecting medical and financial records. Patients may access survivorship and support services as part of their care at the Vanderbilt-Ingram Cancer Center.

Specializations:

• Chemotherapy
• Radiation therapy
• Surgery
• Targeted therapy

Accreditations:

• CEO Cancer Gold Standard
• National Cancer Institute (NCI) Comprehensive Care Center
• National Cancer Institute (NCI) National Clinical Trials Network accreditation
• National Comprehensive Cancer Network (NCCN) accreditation

Mesothelioma Clinical Trials at Vanderbilt-Ingram Cancer Center

The following clinical trials are in progress or actively recruiting participants at Vanderbilt-Ingram Cancer Center:

• Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin

  Conditions:	Advanced Malignant Solid Neoplasm; Advanced Peritoneal Malignant Mesothelioma; Advanced Pleural Malignant Mesothelioma; Recurrent Peritoneal Malignant Mesothelioma; Recurrent Pleural Malignant Mesothelioma; Refractory Malignant Solid Neoplasm; Unresectable Solid Neoplasm
  Last Updated:	May 6, 2019
  Status:	Recruiting

• A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies

  Conditions:	Advanced Malignancies
  Last Updated:	April 26, 2019
  Status:	Active, not recruiting

• A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies

  Conditions:	Cervical Cancer; Microsatellite Instability (MSI)-High Endometrial Cancer; Gastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ]); Esophageal Cancer; Hepatocellular Carcinoma; Melanoma (Uveal Melanoma Excluded); Merkel Cell Carcinoma; Mesothelioma; MSI-high Colorectal Cancer; Non-small Cell Lung Cancer (NSCLC); Ovarian Cancer; Squamous Cell Carcinoma of the Head and Neck (SCCHN); Small Cell Lung Cancer (SCLC); Renal Cell Carcinoma (RCC); Triple-negative Breast Cancer; Urothelial Carcinoma; Diffuse Large B-cell Lymphoma
  Last Updated:	April 10, 2019
  Status:	Recruiting

• Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors

  Conditions:	Metastatic Cancer; Solid Tumors; Colorectal Cancer (CRC); Gastric Cancer; Head and Neck Cancer; Lung Cancer; Renal Cell Carcinoma (RCC); Bladder Cancer; UC (Urothelial Cancer); Mesothelioma
  Last Updated:	November 29, 2018
  Status:	Recruiting

Sources